Physician profile
Enrique Samonte
NPI 1922267152
$1,076.91
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.36 · 2021: $850 · 2022: $193.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $306.27 | 2021 | |
| Novo Nordisk INC | $266.98 | 2021-2022 | |
| Esperion Therapeutics, INC. | $231.19 | 2021 | |
| Abbvie INC. | $137.15 | 2021 | |
| Pfizer INC. | $37.03 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $21.19 | 2021 | |
| Abbott Laboratories | $20.71 | 2022 | |
| Allergan, INC. | $18.71 | 2019 | |
| Bardy Diagnostics, INC. | $15.00 | 2022 | |
| Merck Sharp & Dohme LLC | $14.65 | 2019 | |
| Dynavax Technologies Corporation | $8.03 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Enrique Samonte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.